N/A N=153 Acupuncture for Pain Management During Uterine Aspiration
Pain Acute · Acupuncture
Primary: Visual Analog Scale for Pain (VAS Pain) Score - Acupuncture Versus Routine Care — 39.5; 71.0 score on a scale
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=114 Effects of Catheter Location on Postoperative Analgesia for Continuous Adductor Canal and Popliteal-Sciatic Nerve Blocks
Post-surgical Pain · Total Knee Arthroplasty · Foot/Ankle Surgery
Primary: Pain (Average): Numeric Rating Scale for Pain — 0.5; 3.0 score on a scale
Phase 4 N=80 The Impact Of The Addition Of Budesonide To Low-Pressure, High-Volume Saline Sinus Irrigation For Chronic Rhinosinusitis
Rhinosinusitis · Chronic Eosinophilic Rhinosinusitis · Allergic Rhinosinusitis
Primary: Change in SNOT-22 (Sino-Nasal Outcome Test) — 20.7; 13.6 score on a scale
Phase 2 N=102 Lotemax® Gel 0.5% and Restasis 0.05% in Participants With Mild or Moderate Keratoconjunctivitis Sicca (Dry Eye Disease)
Keratoconjunctivitis Sicca
Primary: Change From Baseline in Corneal Total Fluorescein Staining Score at for the Study Eye at Week 4 — -1.3; -1.7; -1.3 units on a scale — p=0.6199
Phase 3 N=93 Pembrolizumab in Combination With Epacadostat or Placebo in Cisplatin-ineligible Urothelial Carcinoma (KEYNOTE-672/ECHO-307)
UC (Urothelial Cancer)
Primary: Objective Response Rate (ORR) With Pembrolizumab + Epacadostat Versus Pembrolizumab + Placebo — 31.8; 24.5 percentage of participants
Phase 2 N=86 Effects of Switching From ATRIPLA™ (Efavirenz, Tenofovir, Emtricitabine) to MK-1439A (Doravirine, Tenofovir, Lamivudine) in Virologically-Suppressed Participants (MK-1439A-028)
HIV-1 · Central Nervous System
Primary: Percentage of Participants With at Least One Central Nervous System (CNS) Toxicity of at Least Grade 2 Intensity at Week 12 — 41.9; 37.2 Percentage of participants…
Phase 2 N=82 Acupuncture for Chronic Lymphedema
Breast Cancer With Chronic Lymphedema
Primary: Lymphedema as Measured at Baseline and at 6 Weeks — 4.74; 4.82; 4.29; 4.76 cm
N/A N=5 Gastrectomy, Eating Behaviour and GLP-1
Gastric Cancer · Dumping Syndrome
Primary: Nadir Blood Glucose — 3; 4.4 mmol/l — p=0.008
N/A N=87 Telemedicine Management of Chronic Insomnia
Sleep Initiation and Maintenance Disorders · Post-Traumatic Stress Disorders
Primary: Change From Baseline in Insomnia Severity Index Score — 6.68; 5.13 units on a scale — p=0.138
Phase 2 N=202 S1201: Combination Chemo for Patients W/Advanced or Metastatic Esophageal, Gastric, or Gastroesophageal Junction Cancer
Adenocarcinoma of the Gastroesophageal Junction · Esophageal Cancer · Gastric Cancer
Primary: Progression-free Survival (PFS) in High-ERCC1 Patients — 4.7; 5.3 months — p=0.83
Phase 3 N=699 Immunogenicity and Safety Study of GSK Biologicals' Candidate Malaria Vaccine Given at 6, 7.5 and 9 Months of Age in Co-administration With Measles, Rubella and Yellow Fever (YF) Vaccines Followed by a Booster of the Malaria Vaccine.
Malaria · Malaria Vaccines
Primary: Anti-Circumsporozoite (Anti-CS) Antibody Concentrations, One Month Post Dose 3 of SB257049 (Primary Analysis) — 452.87; 422.49 EU/mL
N/A N=27 Objective Assessment of Activity and Sleep Quality In Burst Spinal Cord Stimulation
Chronic Pain
Primary: Change in Activity Levels — -0.17 change in MVPA h/day from baseline value
N/A N=20 Hemospray Versus the Combined Conventional Technique for Endoscopic Hemostasis of Bleeding Peptic Ulcers : A Pilot Study
Bleeding Peptic Ulcers
Primary: Re-bleeding Within 4 Weeks — 3; 1 Participants
N/A N=87 Total Hip Arthroplasty (THA) Surgical Techniques Comparing the Direct Anterior Approach to the Posterior Approach
Osteoarthritis of the Hip
Primary: Returning to Quality of Life by Using Either Anterior Approach Versus Posterior Approach — 40.1; 43.8 score on a scale
N/A N=6 Heart Rate Variability and Prematurity
Premature Birth · Maternal Distress - Delivered · Stress
Primary: Feasibility: Acceptance (Ratio) — 33.3 percentage of <participants>